Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05544799
Recruiting Observational

Case Studies of Patients Who Had Experienced Near Death Experience

NCT05544799 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Hospital
Phase
Observational
Started
2021-01-03
Last updated
2026-02-02

Condition(s) studied

Near Death Experience

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervension

Study summary

An prospective observational study to interview patients who had near death experiences among those who had received intensive care unit intervention during admission in hematology ward.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (≥19yrs) who are in admission in the Hematology ward of Seoul National University Hospital, and one of the following conditions. 1. recovered after cardiopulomary resuscitation 2. recovered after mechanical ventilator 3. recovered after ICU care 4. recovered after emergent operation 5. recovered after Shock, coma, altered mentality 6. Other medical conditions approaching death Exclusion Criteria: 1. Those who do not agree to participate this study 2. Those who can not be interviewed due to insufficient recovery from critical medical problems

Primary outcome measure(s)

  • Incidence of near death experience (NDE) — 5 years
    Incidence of case with NDE scale ≥7 point

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Hospital Seoul South Korea Recruiting

More Seoul National University Hospital trials in South Korea

Lung Cancer Surgery in Sarcopenia Patients With Old Age Active, not recruiting
Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION) Recruiting
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis Recruiting
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer Recruiting
Reduction of Remifentanil-related Complications Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05544799 on ClinicalTrials.gov ↗ ← All trials in South Korea